ReviewDrug discovery today2026
cGAS-STING pathway in lung cancer and emerging therapeutic approaches.
Review in Drug discovery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- cGAS-STING pathway regulated by spatiotemporal heterogeneity of tumor microenvironment and precision therapy strategies in lung cancer.Journal of experimental & clinical cancer research : CR · 2026Review
- Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lung cancer is an aggressive malignancy with one of the highest mortality rates among cancers. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway, a central mediator of immunity, is frequently attenuated in lung cancer through a variety of mechanisms. This attenuation facilitates immune evasion while creating both a significant clinical challenge and a major therapeutic opportunity. Here, we analyze how lung cancer subtypes disrupt the cGAS-STING pathway and evaluate emerging therapeutic strategies, including STING agonism, epigenetic reactivation, metabolic and enzymatic targeting, and combination regimens with immunotherapy and radiotherapy. Precision tuning of cGAS-STING activity offers a promising avenue to reshape the tumor microenvironment and overcome tumor progression in lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.